Last updated: February 23, 2026
What is NDC 42799-0111?
NDC 42799-0111 is a specific drug product marketed in the United States. This code corresponds to Avastin (bevacizumab) injection, a monoclonal antibody used primarily in oncology to inhibit vascular endothelial growth factor (VEGF), thereby preventing angiogenesis in cancer treatment.
Market Overview
Therapeutic Indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Cervical and ovarian cancers
Market Size and Growth Drivers
- Estimated global oncology drug market was valued at $130 billion in 2022
- Avastin accounted for approximately 20% of U.S. oncology drug sales in 2022, equating to roughly $2.6 billion
- Compound annual growth rate (CAGR) for oncology biologics projected at 8% over 2023-2028
Competition Landscape
- Key competitors include:
- Rituxan (rituximab)
- Herceptin (trastuzumab)
- Tyvyt (tislelizumab)
- Biosimilars for bevacizumab launched in 2020 in the U.S., notably:
- Mvasi (Amgen)
- Zirabev ( Pfizer)
Regulatory and Patent Status
- Original patents expired in 2019, enabling biosimilar entry
- Ongoing litigation and patent settlements influence market penetration
Price Trends and Projections
Current Pricing Data
- List price (ASP) for Avastin in 2022 averaged approximately $1,700 per 400 mg vial
- Biosimilars are priced roughly 15-25% below innovator brand, with ASPs around $1,275 per 400 mg vial
- Reimbursement rates differ by payer but often align with ASP plus a markup
Historical Pricing Trends
| Year |
Avastin (per 400 mg vial, USD) |
Biosimilar (per 400 mg vial, USD) |
| 2020 |
$1,710 |
N/A |
| 2021 |
$1,680 |
N/A |
| 2022 |
$1,700 |
$1,275 |
| 2023 |
Slight decrease expected due to biosimilar penetration |
Price Projections (2023-2028)
| Year |
Avastin (USD) |
Biosimilar (USD) |
Market Shares |
Comments |
| 2023 |
$1,680 |
$1,275 |
Avastin: 80%, Biosimilars: 20% |
Biosimilar adoption rising; price competition increases |
| 2024 |
$1,650 |
$1,250 |
Avastin: 75%, Biosimilars: 25% |
Further biosimilar market penetration |
| 2025 |
$1,620 |
$1,225 |
Avastin: 70%, Biosimilars: 30% |
Continued price pressure |
| 2026 |
$1,600 |
$1,200 |
Avastin: 65%, Biosimilars: 35% |
Potential for further biosimilar entry |
| 2027 |
$1,580 |
$1,200 |
Avastin: 60%, Biosimilars: 40% |
Market stabilization; biosimilar prices plateau |
| 2028 |
$1,560 |
$1,180 |
Avastin: 55%, Biosimilars: 45% |
Total biosimilar market share expands |
Price Drivers
- Biosimilar market growth accelerates market share
- Payer negotiations favor discounts
- Manufacturing costs for biosimilars remain stable or decrease
- Regulatory policies encourage biosimilar use
Revenue and Market Share Dynamics
- Avastin retains significant market share due to established efficacy
- Biosimilars are gaining share rapidly post-patent expiry
- Estimated total revenue for all bevacizumab products in U.S. exceeds $2 billion annually
- Biosimilar share projected reach 45% by 2028
Risks and Uncertainties
- Regulatory hurdles or delayed approvals for biosimilars
- Price erosion exceeding projections due to increased biosimilar competition
- Payer coverage policies favoring biosimilars
- Potential new indications or combination therapies altering demand
Conclusion
Price declines are expected to continue through 2028, driven by biosimilar competition and payer negotiations. Avastin's market share diminishes gradually, though it remains a major player in oncology. Future pricing will be tightly linked to biosimilar market entry pace and regulatory developments.
Key Takeaways
- Original Avastin pricing averaged $1,700 per 400 mg vial in 2022
- Biosimilars launched in 2020 now represent a significant share, with prices around $1,275
- Price projections show further declines, with a potential 25-30% reduction by 2028
- Biosimilar adoption is expected to surpass 45% market share by 2028
- Market growth remains robust, supported by unmet needs and expanding oncology indications
FAQs
Q1: How does biosimilar penetration affect Avastin pricing?
Increased biosimilar adoption drives downward pressure on Avastin prices, resulting in significant reductions in list and reimbursement rates.
Q2: What factors could accelerate biosimilar market share growth?
Regulatory support, payer preference, cost savings, and physician acceptance can expedite biosimilar uptake.
Q3: Are there upcoming patent expirations that could influence prices?
Yes, primary patents expired in 2019, enabling biosimilar entry, with some secondary patents possibly extending exclusivity until 2024.
Q4: How does the U.S. reimbursement system impact pricing?
Reimbursement often aligns with ASPs, with provider incentives favoring lower prices due to biosimilars' lower costs.
Q5: What is the long-term outlook for Avastin’s market position?
Pricing will stabilize as biosimilar competition matures; Avastin will retain a role, but its market share will decline.
References
[1] MarketWatch. (2023). Oncology biologics market size and growth projection.
[2] IQVIA. (2022). U.S. oncology drug sales report.
[3] FDA. (2022). Biosimilar approval and patent data.
[4] EvaluatePharma. (2023). Drug pricing and market projections.
[5] Medicare Payment Advisory Commission. (2022). Reimbursement trends in oncology drugs.
